China greenlights more TIGIT trials
China has approved clinical trials for tiragolumab, Roche’s anti-TIGIT drug currently being tested as a potential treatment for various cancers, records from its Center for Drug Evaluation show.
The Swiss pharma’s China application for the immunotherapy includes treating liver cancer as a monotherapy, and in combination with Tecentriq, treating extensive-stage small cell lung cancer, esophageal squamous cell carcinoma, and non-small cell lung cancer.
TIGIT, short for T cell immunoreceptor with Ig and ITIM domains, is a checkpoint protein on immune cells that tumor cells disable to prevent its anti-tumor activity. Tiragolumab blocks TIGIT’s interaction with the tumor cells to maintain the immune response against cancer.
In a Phase 2 trial readout in May, Roche showed that tiragolumab in combination with its PD-L1 drug Tecentriq delayed tumor progression in a subset of patients with non-small cell lung cancer.
Roche’s novel drug will be up against at least two Chinese biotechs also developing anti-TIGIT immunotherapies. In June, Suzhou-based Innovent Biologics launched its early stage trial for IBI939, in combination with its PD-1 drug Tyvyt. Meanwhile, Beigene is also combining its PD-1 therapy tislelizumab, with BGB-A1217, its anti-TIGIT molecule, which the company claims is four times more potent than tiragolumab in preclinical studies.
The Swiss pharma’s China application for the immunotherapy includes treating liver cancer as a monotherapy, and in combination with Tecentriq, treating extensive-stage small cell lung cancer, esophageal squamous cell carcinoma, and non-small cell lung cancer.
TIGIT, short for T cell immunoreceptor with Ig and ITIM domains, is a checkpoint protein on immune cells that tumor cells disable to prevent its anti-tumor activity. Tiragolumab blocks TIGIT’s interaction with the tumor cells to maintain the immune response against cancer.
In a Phase 2 trial readout in May, Roche showed that tiragolumab in combination with its PD-L1 drug Tecentriq delayed tumor progression in a subset of patients with non-small cell lung cancer.
Roche’s novel drug will be up against at least two Chinese biotechs also developing anti-TIGIT immunotherapies. In June, Suzhou-based Innovent Biologics launched its early stage trial for IBI939, in combination with its PD-1 drug Tyvyt. Meanwhile, Beigene is also combining its PD-1 therapy tislelizumab, with BGB-A1217, its anti-TIGIT molecule, which the company claims is four times more potent than tiragolumab in preclinical studies.
No hay comentarios:
Publicar un comentario